ヒトパピローマウイルス(HPV)治療薬の世界市場2019-2023

◆英語タイトル:Global Human Papillomavirus (HPV) Therapeutics Market 2019-2023
◆商品コード:IRTNTR30751
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年1月28日
◆ページ数:113
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥312,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、ヒトパピローマウイルス(HPV)治療薬の世界市場について調査・分析し、市場概要、市場環境、ヒトパピローマウイルス(HPV)治療薬市場規模、投与ルート別(非経口、局所)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・ヒトパピローマウイルス(HPV)治療薬の世界市場概要
・ヒトパピローマウイルス(HPV)治療薬の世界市場環境
・ヒトパピローマウイルス(HPV)治療薬の世界市場動向
・ヒトパピローマウイルス(HPV)治療薬の世界市場規模
・ヒトパピローマウイルス(HPV)治療薬の世界市場:業界構造分析
・ヒトパピローマウイルス(HPV)治療薬の世界市場:投与ルート別(非経口、局所)
・ヒトパピローマウイルス(HPV)治療薬の世界市場:地域別市場規模・分析
・ヒトパピローマウイルス(HPV)治療薬の北米市場規模・予測
・ヒトパピローマウイルス(HPV)治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・ヒトパピローマウイルス(HPV)治療薬のアジア太平洋市場規模・予測
・ヒトパピローマウイルス(HPV)治療薬の主要国分析
・ヒトパピローマウイルス(HPV)治療薬の世界市場:意思決定フレームワーク
・ヒトパピローマウイルス(HPV)治療薬の世界市場:成長要因、課題
・ヒトパピローマウイルス(HPV)治療薬の世界市場:競争環境
・ヒトパピローマウイルス(HPV)治療薬の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market
Technological advances in diagnostics to drive market growth. The diagnostic methods that are currently available in the market include Pap test, colposcopy, and HPV DNA test. Pap test is a screening procedure for cervical cancer, in which the presence of precancerous or cancerous cells is identified on the cervix. Colposcopy is a more advanced technique like a Pap test, which allows the examiner to take abnormal cell tissues from the cervix. Technavio’s analysts have predicted that the human papillomavirus (HPV) therapeutics market will register a CAGR of nearly 9% by 2023.
Market Overview
Advent of vaccines
The global HPV therapeutics market witnessed strong advances in terms of prevention of diseases caused by HPV. This is primarily due to the increasing research on developing highly advanced vaccines with a longer half-life. Vaccines were proved to have strong efficacy toward the prevention of various disease-causing viruses and highly effective toward the prevention of various indications caused by HPV.
Multiple-dose schedules of vaccines
Despite the availability of vaccines for the prevention of indications caused by HPV, the market faces a challenge from their recurring doses. As the vaccines that are currently approved for HPV are developed for administering through invasive methods such as subcutaneous route, the need for multiple doses affects the patient adherence toward the completion of the dose cycle.
For the detailed list of factors that will drive and challenge the growth of the human papillomavirus (HPV) therapeutics market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including ALLERGAN and Bausch Health the competitive environment is quite intense. Factors such as the advent of vaccines and the technological advances in diagnostics, will provide considerable growth opportunities to human papillomavirus (HPV) manufactures. ALLERGAN, Bausch Health, GlaxoSmithKline, Lee’s Pharmaceutical Holdings, and Merck Sharp & Dohme are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY ROA
• Market segmentation by RoA
• Comparison by RoA
• Parenteral – Market size and forecast 2018-2023
• Topical – Market size and forecast 2018-2023
• Market opportunity by RoA
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• ALLERGAN
• Bausch Health
• GlaxoSmithKline plc.
• Lee’s Pharmaceutical Holdings Limited
• Merck Sharp & Dohme Corp.
PART 13: APPENDIX
• Research methodology
• List of abbreviations

Exhibit 01: Years in consideration
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: RoA – Market share 2018-2023 (%)
Exhibit 19: Comparison by RoA
Exhibit 20: Parenteral – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Parenteral – Year-over-year growth 2019-2023 (%)
Exhibit 22: Topical – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Topical – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by RoA
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America – Year-over-year growth 2019-2023 (%)
Exhibit 30: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 31: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 32: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 33: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 34: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 36: Key leading countries
Exhibit 37: Market opportunity
Exhibit 38: Decision framework
Exhibit 39: Impact of drivers and challenges
Exhibit 40: Vendor landscape
Exhibit 41: Landscape disruption
Exhibit 42: Vendors covered
Exhibit 43: Vendor classification
Exhibit 44: Market positioning of vendors
Exhibit 45: ALLERGAN – Vendor overview
Exhibit 46: ALLERGAN – Product segments
Exhibit 47: ALLERGAN – Organizational developments
Exhibit 48: ALLERGAN – Geographic focus
Exhibit 49: ALLERGAN – Segment focus
Exhibit 50: ALLERGAN – Key offerings
Exhibit 51: ALLERGAN – Key customers
Exhibit 52: Bausch Health – Vendor overview
Exhibit 53: Bausch Health – Product segments
Exhibit 54: Bausch Health – Organizational developments
Exhibit 55: Bausch Health – Geographic focus
Exhibit 56: Bausch Health – Segment focus
Exhibit 57: Bausch Health – Key offerings
Exhibit 58: Bausch Health – Key customers
Exhibit 59: GlaxoSmithKline plc. – Vendor overview
Exhibit 60: GlaxoSmithKline plc. – Business segments
Exhibit 61: GlaxoSmithKline plc. – Organizational developments
Exhibit 62: GlaxoSmithKline plc. – Geographic focus
Exhibit 63: GlaxoSmithKline plc. – Segment focus
Exhibit 64: GlaxoSmithKline plc. – Key offerings
Exhibit 65: GlaxoSmithKline plc. – Key customers
Exhibit 66: Lee’s Pharmaceutical Holdings Limited – Vendor overview
Exhibit 67: Lee’s Pharmaceutical Holdings Limited – Business segments
Exhibit 68: Lee’s Pharmaceutical Holdings Limited – Organizational developments
Exhibit 69: Lee’s Pharmaceutical Holdings Limited – Segment focus
Exhibit 70: Lee’s Pharmaceutical Holdings Limited – Key offerings
Exhibit 71: Lee’s Pharmaceutical Holdings Limited – Key customers
Exhibit 72: Merck Sharp & Dohme Corp. – Vendor overview
Exhibit 73: Merck Sharp & Dohme Corp. – Business segments
Exhibit 74: Merck Sharp & Dohme Corp. – Organizational developments
Exhibit 75: Merck Sharp & Dohme Corp. – Geographic focus
Exhibit 76: Merck Sharp & Dohme Corp. – Segment focus
Exhibit 77: Merck Sharp & Dohme Corp. – Key offerings
Exhibit 78: Merck Sharp & Dohme Corp. – Key customers
Exhibit 79: Validation techniques employed for market sizing
Exhibit 80: List of abbreviations



【掲載企業】

ALLERGAN、Bausch Health、GlaxoSmithKline、Lee's Pharmaceutical Holdings、Merck Sharp & Dohme

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ヒトパピローマウイルス(HPV)治療薬の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆